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ABSTRACT
In vitro activity of doripenem and comparator antimicrobial agents was evaluated against 
Gram-negative bacilli recently isolated from Brazilian private hospitals that were enrolled in the 
INVITA-A-DORI Brazilian Study. A total of 805 unique Gram-negative bacilli were collected from 
patients hospitalized at 18 medical centers between May/08 and March/09. Each hospital was asked 
to submit 50 single Gram-negative bacilli isolated from blood, lower respiratory tract or intra- 
abdominal secretions. Bacterial identification was confirmed and antimicrobial susceptibility 
testing was performed using Clinical Laboratory Standards Institute (CLSI) microdilution method 
at a central laboratory. CLSI M100-S21 (2011) or US-FDA package insert criteria (tigecycline) was 
used for interpretation of the antimicrobial susceptibility results. Doripenem was as active as mero-
penem and more active than imipenem against E. coli and K. pneumoniae isolates. A total of 50.0% 
of Enterobacter spp. isolates were resistant to ceftazidime but 85.7% of them were inhibited at 
doripenem MICs ≤ 1 μg/mL. Polymyxin B was the only agent to show potent activity against Aci-
netobacter spp. (MIC50/90, ≤ 0.5/1 μg/mL) and P. aeruginosa (MIC50/90, 1/2 μg/mL). Although high 
rates of imipenem (53.1%) and meropenem (44.5%) resistance were detected among P. aeruginosa, 
doripenem showed MIC50 of 16 μg/mL against imipenem-resistant P. aeruginosa and inhibited a 
greater number of imipenem-resistant P. aeruginosa (10.5%) at MIC values of ≤ 4 μg/mL than did 
meropenem (0.0%). In this study, doripenem showed similar in vitro activity to that of meropenem and 
retained some activity against imipenem-resistant P. aeruginosa isolated from Brazilian medical centers. 
Keywords: carbapenems; Gram-negative bacteria; Brazil.
INTRODUCTION
Doripenem is a novel parenteral 1-β-methyl-
carbapenem with broad-spectrum activity 
against commonly isolated Gram-negative and 
Gram-positive pathogens.1,2 Doripenem, like 
meropenem and ertapenem, is stable to renal 
dehydropeptidase-1 hydrolysis because of the 
presence of a 1-β-methyl constituent on 
the carbapenem nucleus. It also has a sul-
famoylami noethyl-pyrrolidinylthio group in its 
side chain at position 2 that enhances its activity 
against non-fermentative Gram-negative ba-
cilli.1,2 Doripenem acts by inactivating multiple 
essential penicillin binding proteins (PBPs) for 
cell wall biosynthesis resulting in subsequent 
cell death. It has high affinity for PBP1, PBP2, 
and PBP4 of Staphylococcus aureus as well as 
for PBP2, PBP3 and PBP4 of Escherichia coli 
and Pseudomonas aeruginosa. The binding af-
finity of doripenem for PBP2 of P. aeruginosa 
was stronger than that documented for most 
cephalosporins.3,4 In general, doripenem is less 
potent than imipenem, but more potent than 
meropenem, against Gram-positive bacteria. 
Against Gram-negative bacteria, the activity of 
doripenem is similar to that of meropenem but 
superior to that of imipenem.1,5,6 None of the 
clinically available carbapenems are effective 
against E. faecium, methicilin-resistant S. aureus 
or coagulase-negative staphylococci due to poor 
binding affinity to PBP5 and PBP2a, respec-
tively.5,6 Doripenem is stable to hydrolysis by 
most β-lactamases, including penicillinases and 
cephalosporinases produced by Gram-positive 
and Gram-negative bacteria, but not to car-
bapenem hydrolyzing β-lactamases.1,4,7 Thus, 
doripenem like other carbapenems is not active 
against Stenotrophomonas maltophilia as a result 
of its intrinsic metallo-β-lactamase production.1,7 
The favorable spectrum, potency and phar-
macokinetics for doripenem have led to suc-
cessful clinical trial results for intra-abdominal Este é um artigo Open Access sob
 a licença de CC BY-NC-ND
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infections, nosocomial pneumonias, and complicated uri-
nary tract infections.8 In October 2007, the doripenem clinical 
use was approved by the United States Food and Drug 
Administration (US-FDA) for treatment of complicated 
urinary tract and intra-abdominal infections.8 In Europe 
it is also licensed for treatment of nosocomial pneumonia, 
including ventilator-associated pneumonia. 
In general, high resistance rates among key nosocomial 
pathogens have been reported in Brazil.9 However, most 
of these reports originates from surveillance programs 
that have evaluated isolates collected from a few public/ 
teaching hospitals.10 Local surveillance studies are of 
crucial importance to establish the role that a new antimi-
crobial agent might play in a geographic region since local 
variations in the frequency distribution of pathogens and 
antimicrobial susceptibility profiles have been reported. 
Although doripenem has been tested in vitro against clini-
cal isolates collected worldwide, it has been not tested 
against a large collection of pathogens isolated from dis-
tinct Brazilian medical centers. The main objective of this 
study was to evaluate the in vitro activity of doripenem and 
comparator agents against Gram-negative bacilli recently 
isolated from Brazilian private hospitals.
MATERIAL AND METHODS
Participant medical centers
Eighteen private hospitals participated of the INVITA-A-
DORI Brazilian Study. The medical centers were located 
in the cities of Belo Horizonte (2 medical centers), Blume-
nau (1 medical center), Curitiba (1 medical center), Porto 
Alegre (2 medical centers), São Paulo (7 medical centers), 
Rio de Janeiro (3 medical centers), Salvador (1 medical 
center), and São Luís (1 medical center). The selection of 
the participant medical centers was primarily based on the 
criteria that they should have ≥ 200 beds, at least one adult 
intensive care unit and located in cities with more than one 
million inhabitants. 
Bacterial isolates
A total of 806 consecutive Gram-negative bacilli were sub-
mitted between March 2008 and August 2009. By protocol, 
each medical center had to submit Gram-negative bacilli 
collected from patients with diagnosis of pneumonia (20 
isolates; 10 of them from ventilated-associated pneumonia), 
bloodstream infections (20 isolates) and intra-abdominal 
infections (10 isolates) according to the Centers for Dis-
ease Control and Prevention (CDC) definitions.11 Just a 
single isolate per patient was evaluated. All isolates were 
identified at the participating institution by routine meth-
odologies of each laboratory. Upon receipt at the central 
laboratory (UNIFESP, São Paulo), isolates were subcul-
tured to ensure viability and purity. Confirmation of 
species identification was performed with the BD Phoe-
nix™ Automated Microbiology System (BD Diagnostics, 
MD, USA) or conventional methods, as required. 
Susceptibility testing
Antimicrobial susceptibility testing was performed by the 
broth microdilution method, following recommendations 
of the Clinical and Laboratory Standards Institute (CLSI).12 
Antimicrobial powders were obtained from the respective 
manufacturers and microdilution plates were prepared 
by TREK Diagnostics (West Sussex, England). Susceptibil-
ity results were interpreted according to CLSI document 
M100-S21 for all comparison agents13 except for doripenem8 
and tigecycline.14 Quality control was performed by testing 
E. coli ATCC 25922 and P. aeruginosa ATCC 27853.
RESULTS
A total of 805 isolates were collected as part of the 
INVITA-A-DORI Brazilian Study. The bacterial iso-
lates were collected mainly from patients diagnosed with 
bloodstream (40.9%), lower respiratory tract (39.1%) and 
intra-abdominal (15.4%) infections. The most frequent 
Gram-negative bacilli collected were P. aeruginosa (26.6%); 
E. coli (18.9%); Klebsiella spp. (18.3%); Acinetobacter spp. 
(13.9%); Enterobacter spp. (8.7%); and Serratia spp. (6.3%). 
They accounted for 92.7% of the total number of isolates 
collected as shown in Table 1.
The antimicrobial susceptibility profile of the most 
frequent Enterobacteriaceae isolates is shown in Table 2. 
Doripenem (MIC50, ≤ 0.12 µg/mL; 97.4% suscepti-
ble) was as potent as meropenem (MIC50, ≤ 0.12 µg/mL; 
98.0% susceptible) and at least two-fold more potent than 
imipenem (MIC50, 0.25 µg/mL; 94.7% susceptible) against 
E. coli. Amikacin (MIC50, ≤ 4 µg/mL; 97.4% susceptible), 
tigecycline (MIC50, 0.5 µg/mL; 97.4% susceptible), and 
polymyxin B (MIC50, ≤ 0.5 µg/mL; 96.7% susceptible) 
also showed good in vitro activity against E. coli. Doripe- 
nem (MIC50, ≤ 0.12 µg/mL; 85.0% susceptible) and 
meropenem (MIC50, ≤ 0.12 µg/mL; 83.7% susceptible) 
were the most active compounds against Klebsiella spp. 
followed by imipenem (MIC50, 0.5 µg/mL; 78.2% suscepti-
ble), polymyxin B (MIC50, ≤ 0.5 µg/mL; 91.2% susceptible) 
and tigecycline (MIC50, 1 µg/mL; 95.2% susceptible). Cef-
tazidime (MIC50, 2 µg/mL; 53.7% susceptible) was four- and 
sixteen-fold more potent than cefepime (MIC50, 8 µg/mL; 
51.7% susceptible) and ceftriaxone (MIC50, 32 µg/mL; 39.5% 
susceptible) against Klebsiella spp. isolates, respectively. Against 
the 70 Enterobacter spp. isolates tested, doripenem (MIC50, 
0.25 µg/mL) and meropenem (MIC50, 0.12 µg/mL) were at 
least eight-fold more potent than imipenem (MIC50, 2 µg/mL) 
as shown in Table 2. Although cefepime (MIC50, 2 µg/mL) was 
four- and eight-fold more potent than ceftazidime (MIC50, 
8 µg/mL) and ceftriaxone (MIC50, 16 µg/mL), respectively, 
Doripenem activity against Brazilian isolates
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Table 1. Distribution of the most frequent pathogens 
tested by the INVITA-A-DORI Brazilian Study
Bacterial genus/species Amount (%)
Pseudomonas spp.a 214 (26.6)
Escherichia coli 152 (18.9)
Klebsiella spp.b 147 (18.3)
Acinetobacter spp.c 112 (13.9)
Enterobacter spp.d 70 (8.7)
Serratia spp.e 51 (6.3)
Proteus spp.f 21 (2.6)
Citrobacter spp.g 12 (1.5)
Morganella morgannii 12 (1.5)
Burkholderia cepacea 5 (0.6)
Salmonella spp.h 5 (0.6)
Alcaligenes xylosoxidans 1 (0.1)
Delfia acidovorans 1 (0.1)
Hafnia spp. 1 (0.1)
Pantoea spp. 1 (0.1)
Providencia stuartii 1 (0.1)
Total 806 (100.0)
a P. aeruginosa (209), P. fluorescens (02), P. putida (01),  
P. stutizeri (01), Pseudomonas spp. (01).
b K. pneumoniae (141), K. oxytoca (06).
c Acinetobacter baumannii (103), A. lwoffii (02), Acinetobacter 
spp. (07).
d E. cloacae (45), E. aerogenes (19), Enterobacter spp. (05), 
E. amnigenus (01).
e S. marcescens (48), Serratia spp. (02), S. liquefaciens (01).
f P. mirabilis (20), P. vulgaris (01).
g C. freundii (05), C. koseri (03), Citrobacter spp. (02), 
C. braaki (01), C. amalonaticus (01).
h Salmonella spp. (04), S. enterica (01).
against Enterobacter spp., only 58.6% of strains were sus-
ceptible to this compound. Amikacin inhibited 67.1% of 
Enterobacter spp. In contrast, tigecycline (MIC50, 1µg/mL) 
showed a reasonable activity against Enterobacter spp. inhib-
iting 91.4% of strains at concentrations ≤ 2 µg/mL. Dorip-
enem (MIC50/90, 0.25/4 µg/mL) and meropenem (MIC50/90, 
0.25/2 µg/mL) were also very potent against cefepime 
non-susceptible Enterobacter spp. and eight-fold more potent 
than imipenem (MIC50/90, 2/8 µg/mL). The highest MIC val-
ues for doripenem and meropenem against non-susceptible 
Enterobacter spp. were 8 µg/mL and ≥ 16 µg/mL, respectively. 
Doripenem (MIC50, 0.25 μg/mL) and meropenem (MIC50, 
0.25 μg/mL) exhibited a similar potency to that of levofloxa-
cin (MIC50, ≤ 0.5 μg/mL) against S. marcescens isolates. The 
highest susceptibility rates were observed for the carbap-
enems followed by amikacin (76.5%), tigecycline (74.5%), 
and cefepime (70.6%) as shown in Table 2.
P. aeruginosa and Acinetobacter spp. showed high resist-
ance rates to all compounds tested except for polymyxin B 
(Table 3). This compound was the most active antimicro-
bial agent against P. aeruginosa (MIC50, 1 μg/mL; 98.6% 
susceptible) and Acinetobacter spp. (MIC50, ≤ 0.5 μg/mL; 
98.2% susceptible). Against P. aeruginosa, piperacillin/
tazobactam (57.4%) showed the second highest suscep-
tibility rate. Doripenem and meropenem were equally 
potent against Acinetobacter spp. (MIC50, > 8 μg/mL) and 
P. aeruginosa (MIC50, 8 μg/mL); however, doripenem in-
hibited a greater number of P. aeruginosa isolates (47.3%) 
at MIC values ≤ 4 μg/mL than did meropenem (39.1%) or 
imipenem (38.6%; Table 4). Doripenem (MIC50, 16 µg/mL) 
was more active than meropenem (MIC50, > 8 µg/mL) against 
imipenem-resistant P. aeruginosa isolates, and inhibited 
10.5% of imipenem-resistant P. aeruginosa, while meropen-
em inhibited none of these strains at MIC values of 4 µg/mL 
(Table 4). Polymyxin B was the only agent active 
against 97.8% imipenem-resistant Acinetobacter spp. 
(MIC50/90, ≤0.5/1 µg/mL) and 99.1% imipenem-resistant 
P. aeruginosa (MIC50/90, 1/2 µg/mL). Its potency was slightly 
affected by the carbapenem-resistant phenotype since 100% 
of imipenem-susceptible Acinetobacter spp. and 98.8% of 
imipenem-susceptible P. aeruginosa were inhibited at poly-
myxin B concentrations of 1 and 2 µg/mL, respectively. Only 
1.8% of Acinetobacter spp. isolates showed polymyxin B 
MIC results ≥ 4 µg/mL and were classified as resistant by 
CLSI criteria. Full polymyxin B resistance was not detected 
among P. aeruginosa isolates.
DISCUSSION
The emergence of antimicrobial resistance represents one 
of the greatest public health threats. An area of particular 
concern involves Gram-negative pathogen resistance, where 
few agents are effective or in late-stage of development.15 
ESBL-producing Enterobacteriaceae have been established 
as a major cause of nosocomial-acquired infections. Usually, 
ESBL-producing Enterobacteriaceae also carry genes encod-
ing mechanisms of resistance to other antimicrobial classes 
such as quinolones, aminoglycosides, and tetracyclines.15,16 
Enterobacteriaceae resistant to broad-spectrum cephalo-
sporins due to AmpC derepression have also become more 
frequent in the nosocomial setting.15 In addition, ESBL en-
coding genes have spread out to other bacterial species than 
E. coli and Klebsiella spp. and reached the community set-
ting.17,18 In this manner, carbapenems have become the drug 
of choice for treatment of serious ESBL and derepressed 
AmpC infections.15
Doripenem represents an attractive option among the 
carbapenems since (I) it has potent in vitro activity against 
many Gram-negative and -positive pathogens;1,4,19,20 (II) low-
er propensity to select for resistance;21-23 (III) safe tolerability 
profile with lower seizure potential than imipenem;4,8,24 and 
Gales, Azevedo, Cereda, et al.
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Table 2. In vitro activity of doripenem in comparison to selected antimicrobial agents tested against the main 
Enterobacteriaceae pathogens collected by the INVITA-A-DORI Brazilian Study
Organism (no. tested)/                                            MIC (μg/mL)                     % by categoryª 
Antimicrobial agent 50% 90% Range Susceptible Resistant
E. coli (152)      
	 Doripenem	 ≤	0.12	 0.25	 ≤	0.12	to	>	4	 97.4	 1.3
	 Meropenem	 ≤	0.12	 0.25	 ≤	0.12	to	8	 98.0	 1.4
	 Imipenem	 0.25	 1	 ≤	0.12	to	8	 94.7	 2.7
	 Piperacillin/tazobactam	 2	 >	64	 ≤	2	to	>	64	 83.6	 11.2
	 Ceftriaxone	 ≤	0.25	 >	32	 ≤	0.25	to	>	32	 69.7	 24.9
	 Ceftazidime	 0.25	 16	 ≤	0.12	to	>	16	 82.2	 13.1
	 Cefepime	 ≤	0.12	 >	16	 ≤	0.12	to	>	16	 83.6	 14.5
	 Cefoxitin	 ≤	4	 >	16	 ≤	4	to	>	16	 72.4	 17.1
	 Aztreonam	 ≤	1	 >	16	 ≤	1	to	>	16	 78.9	 18.4
	 Levofloxacin	 4	 >	4	 ≤	0.5	to	>	4	 48.0	 48.0
	 Amikacin	 ≤	4	 8	 ≤	4	to	>	32	 97.4	 1.3
	 Polymyxin	B	 ≤	0.5	 1	 ≤	0.5	to	>	4	 96.7	 1.3b
	 Tigecycline	 0.5	 1	 0.12	to	>	4	 97.4	 0.7
Klebsiella spp. (147)     
 Doripenem	 ≤	0.12	 4	 ≤	0.12	to	>	16	 85.0	 1.3
	 Meropenem	 ≤	0.12	 4	 ≤	0.12	to	>	8	 83.7	 10.9
	 Imipenem	 0.5	 4	 ≤	0.12	to	>	8	 78.2	 10.2
	 Piperacillin/tazobactam	 8	 64	 ≤	2	to	>	64	 57.1	 36.1
	 Ceftriaxone	 32	 >	32	 ≤	0.25	to	>	32	 39.5	 57.8
	 Ceftazidime	 2	 >	16	 ≤	0.12	to	>16	 53.7	 36.0
	 Cefepime	 8	 >	16	 ≤	0.12	to	>16	 51.7	 47.6
	 Cefoxitin	 8	 >	16	 ≤	4	to	>	16	 52.4	 29.9
	 Aztreonam	 8	 >	16	 ≤	1	to	>	16	 46.9	 47.0
	 Levofloxacin	 2	 >	4	 ≤	0.5	to	>	4	 52.4	 40.1
	 Amikacin	 ≤	4	 32	 ≤	4	to	>	32	 87.8	 4.1
	 Polymyxin	B	 ≤	0.5	 2	 ≤	0.5	to	>	4	 91.2	 4.8b
 Tigecycline 1 2 0.12 to 4 95.2 0.0
Enterobacter spp. (70)     
	 Doripenem	 0.25	 1	 ≤	0.12	to	>	16	 90.0	 5.7
	 Meropenem	 0.12	 0.5	 ≤	0.12	to	>	8	 94.3	 2.8
	 Imipenem	 2	 4	 0.25	to	>	8	 28.6	 25.7
	 Piperacillin/tazobactam	 64	 >	64	 ≤	2	to	>	64	 42.9	 38.6
	 Ceftriaxone	 16	 >	32	 ≤	0.25	to	>	32	 34.3	 61.5
	 Ceftazidime	 8	 >	16	 ≤	0.12	to	>	16	 47.1	 50.0
	 Cefepime	 2	 >	16	 ≤	0.12	to	>	16	 58.6	 37.1
	 Cefoxitin	 >	16	 >	16	 ≤	8	to	>	16	 1.4	 92.9
	 Aztreonam	 16	 >	16	 ≤	1	to	>	16	 45.7	 52.9
	 Levofloxacin	 1	 >	4	 ≤	0.5	to	>	4	 54.3	 45.7
	 Amikacin	 ≤	4	 >	32	 ≤	4	to	>	32	 67.1	 27.1
	 Polymyxin	B	 ≤	0.5	 >	4	 ≤	0.5	to	>	4	 77.1	 20.0b
 Tigecycline 1 2 0.25 to 4 91.4 0.0
Doripenem activity against Brazilian isolates
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Table 2. In vitro activity of doripenem in comparison to selected antimicrobial agents tested against the main 
Enterobacteriaceae pathogens collected by the INVITA-A-DORI Brazilian Study (Cont.)
Organism (No. tested)/                                            MIC (μg/mL)                     % by categoryª 
Antimicrobial agent 50% 90% Range Susceptible Resistant
Serratia spp. (51)     
 Doripenem	 0.25	 8	 ≤	0.12	to	>	16	 78.4	 15.7
	 Meropenem	 0.25	 4	 ≤	0.12	to	>	8	 84.3	 11.8
	 Imipenem	 2	 8	 0.12	to	>	8	 47.1	 11.8
	 Piperacillin/tazobactam	 16	 >	64	 ≤	2	to	>	64	 54.2	 35.3
	 Ceftriaxone	 32	 >	32	 ≤	0.25	to	>	32	 45.1	 52.9
	 Ceftazidime	 2	 >	16	 ≤	0.12	to	>	16	 62.7	 25.5
	 Cefepime	 4	 >	16	 ≤	0.12	to	>	16	 72.5	 23.5
	 Aztreonam	 2	 >	16	 ≤	1	to	>	16	 58.8	 35.3
	 Levofloxacin	 ≤	0.5	 >	4	 ≤	0.5	to	>	4	 68.6	 25.5
	 Amikacin	 ≤	4	 32	 ≤	4	to	>	32	 76.5	 9.8
	 Polymyxin	B	 >	4	 >	4	 0.5	to	>	4	 7.8	 90.2b
	 Tigecycline	 2	 4	 0.5	to	>	4	 74.5	 9.8
a Breakpoint criteria established by CLSI document M100-S21, except for doripenem and tigecycline, where FDA breakpoints 
were applied.
b According to breakpoints established by CLSI for P. aeruginosa	(≤	2	µg/mL	for	susceptibility	and	≥	8	µg/mL	for	resistance).	
Table 3. In vitro activity of doripenem in comparison to selected antimicrobial agents tested against  
non-fermentative Gram-negative pathogens collected by the INVITA-A-DORI Brazilian Study
Organism (No. tested)/   MIC (μg/mL)                   % by categoryª 
Antimicrobial agent  50% 90% Range Susceptible Resistant
P. aeruginosa (209)     
	 Doripenem	 8	 >	16	 ≤	0.12	to	>	16	 39.7	 _b
	 Meropenem	 8	 >	8	 ≤	0.12	to	>	8	 40.7	 44.5
	 Imipenem	 >	8	 >	8	 ≤	0.5	to	>	8	 40.2	 53.1
	 Piperacillin/tazobactam	 64	 >	64	 ≤	2	to	>	64	 57.4	 42.6
	 Ceftazidime	 16	 >	16	 ≤	1	to	>	16	 44.5	 45.5
	 Cefepime	 16	 >	16	 ≤	1	to	>	16	 45.0	 43.5
	 Aztreonam	 >	16	 >	16	 ≤	1	to	>	16	 26.8	 54.5
	 Levofloxacin	 >	4	 >	4	 ≤	0.5	to	>	4	 43.1	 52.2
	 Polymyxin	B	 1	 2	 ≤	0.5	to	>	4	 98.6	 0.0
Acinetobacter spp. (112)     
	 Doripenem	 >	16	 >	16	 ≤	0.12	to	>	16	 12.5	 _b
	 Meropenem	 >	8	 >	8	 ≤	0.12	to	>	8	 15.2	 82.1
	 Imipenem	 >	8	 >	8	 0.5	to	>	8	 16.1	 82.1
	 Piperacillin/tazobactam	 >	64	 >	64	 ≤	2	to	>	64	 10.7	 87.5
	 Ceftriaxone	 >	32	 >	32	 ≤	0.25	to	>32	 6.3	 87.5
	 Ceftazidime	 >	16	 >	16	 ≤	0.25	to	>	16	 15.2	 83.0
	 Cefepime	 >	16	 >	16	 ≤	0.12	to	>	16	 13.4	 83.0
	 Levofloxacin	 >	4	 >	4	 ≤	0.5	to	>	4	 10.7	 83.9
	 Polymyxin	B	 ≤	0.5		 1	 ≤	0.5	to	>	4	 98.2	 1.8
	 Tigecycline	 1	 4	 0.012	to	>	4	 86.6	 3.6
a Breakpoint criteria established by CLSI document M100-S21, except for doripenem and tigecycline, where FDA breakpoints 
were applied.
b Interpretative criteria not established by CLSI or FDA.
Gales, Azevedo, Cereda, et al.
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Table 4. Cumulative frequency distributions of doripenem, meropenem and polymyxin B against imipenem- 
resistant Acinetobacter spp. and P. aeruginosa isolated from Brazilian patients (INVITA-A-DORI Brazilian Study)
                                             Cumulative % inhibited at MIC (μg/mL)
Organism 
                   Doripenem       Meropenem           Polymyxin B
 
(no. of isolates)
	 	 	 ≤	1	 2	 4	 8	 16	 >	16	 ≤	1	 2	 4	 8	 >	8	 ≤	0.5	 1	 2	 4	 >	4
Acinetobacter  
spp. (112)                
 Imipenem- 
0.0 0.0 1.1 1.1 5.4 100.0 0.0 0.0 0.0 0.0 100.0 88.0 96.7 97.8 100.0
  
 resistant (92)
 Intermediate 
0.0 0.0 0.0 50.0 100.0  0.0 0.0 50.0 100.0  50.0 50.0 100.0  
 
 to imipenem (2)
 Imipenem- 
77.8 94.4 100.0    83.3 88.9 88.9 100.0  77.8 100.0   
 
 susceptible (18)
P. aeruginosa (209)                
 Imipenem- 
0.0 0.0 10.8 40.5 64.0 100.0 0.0 0.0 0.0 20.7 100.0 3.6 77.5 99.1 100.0
  
 resistant (111)
 Intermediate 
21.4 35.7 71.4 85.7 92.9 100.0 21.4 28.6 57.1 71.4 100.0 14.3 71.4 92.9 100.0
  
 to imipenem (14)
 Imipenem- 
73.8 92.9 96.4 98.8 100.0  76.2 84.5 91.7 98.8 100.0 14.3 75.0 98.8 100.0
  
 susceptible (84)
(IV) extended solution stability at room temperature.4,8,25 
Sakyo et al.21 have shown that the potency of carbapenems 
in preventing the growth of the carbapenem-resistant 
P. aeruginosa mutants differed for doripenem, imipenem, 
and meropenem. Mutants were not selected on agar plates 
containing ½ or ¼ MIC doripenem at a frequency of greater 
than 10-9 per cell per generation, whereas mutants of each 
P. aeruginosa strain were selected on agar containing mero-
penem or imipenem at frequencies of 10-7 to 10-9 per cell 
per generation. Other resistance selection experiments have 
reported similar results.26 Furthermore, a clinical study eval-
uating doripenem pre- and post-treatment of urinary tract 
infections showed that microbiological failures were more 
frequently associated with the acquisition of a new pathogen 
than by emergence of resistant isolates.27 
Although a considerable number of studies have re-
ported the potent in vitro activity of doripenem against 
Gram-negative pathogens, scarce studies have reported the 
activity of this compound against bacterial pathogens iso-
lated from Brazilian hospitals.19 Since the susceptibility rates 
may vary from distinct hospitals located within the same 
geographic area due to epidemiological factors, we aimed 
to evaluate the activity of this agent against Gram-negative 
pathogens isolated from Brazilian private hospitals. Inter-
estingly, the antimicrobial resistance rates observed among 
Gram-negative bacilli isolates collected from private hos-
pitals were higher than those previously reported by other 
surveillance studies that evaluated bacterial isolates mostly 
collected from public/teaching hospitals.10,19 It was expected 
that the resistance rates would have been lower in private 
institutions since compliance to infection control policies is 
assumed to be higher in these institutions than in the public 
hospitals that sometimes experiment scarcity of resources. 
The high resistance rates observed in this study could also 
be partially attributed to the high percentage of Gram-neg-
ative pathogens causing nosocomial-acquired bloodstream 
or lower respiratory tract infections. Our data also reinforce 
the concept that the level of patient’s assistance probably im-
pacts more in the antimicrobial resistance rates than hospi-
tal’s administrative category, public or private. 
The increased MIC90 values for carbapenems against En-
terobacteriaceae, especially K. pneumoniae, noted in this study 
might be related to the sporadic occurrence of metallo-beta-
lactamase or mainly KPC (Klebsiella pneumoniae carbapen-
emase) producers, which has been described in some Brazil-
ian medical centers.28-30 P. aeruginosa and Acinetobacter spp. 
showed high resistance rates to all compounds tested ex-
cept polymyxin B. Doripenem also demonstrated potent 
activity against wild type Acinetobacter spp. and P. aerugino-
sa, and was more active than meropenem against imipenem-
resistant P. aeruginosa isolates. Doripenem retained a degree 
of activity against imipenem- and/or meropenem-resistant 
P. aeruginosa. Specifically, among those P. aeruginosa with 
imipenem MIC values ≥ 8 μg/mL, 10.8% were susceptible to 
Doripenem activity against Brazilian isolates
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doripenem at ≤ 4 μg/mL (Table 4). Although this categori-
zation is based on a MIC value above the current US-FDA 
breakpoints, pK/pD studies have shown a ≥ 90% probability 
of target attainment for isolates possessing doripenem MICs 
≤ 8 µg/mL, when higher dosages in prolonged infusion 
(1 g tid in 4-h infusion) were given.31 In addition, it has 
been reported that doripenem prolonged regimens, particu-
larly at the 1-g dose with the 4-h infusion, achieved higher 
cell kill and resistance suppression rates against wild-type 
P. aeruginosa.32 Since the current US-FDA breakpoints were 
established based on the licensed dosage (500 mg tid in 1-h 
infusion), modifications in the doripenem breakpoints for 
non-fermentative baciili are also expected in the near fu-
ture. By contrast, doripenem showed little potential against 
imipenem-resistant Acinetobacter spp. isolates more than 
90.5% showed MIC results at ≥ 8 μg/mL.
Doripenem is not hydrolyzed by ESBL and AmpC 
enzymes; however, like other carbapenems, doripenem 
remains labile to most carbapenemases.26,33 Among 
carbapenemases, metallo-beta-lactamases (MβLs) are con-
sidered the most prevalent among non-fermentative bacilli. 
In Brazilian hospitals, the dissemination of an endemic clone 
P. aeruginosa producer of SPM-1, which is a MβL, has 
been reported.34 In addition, carbapenems are generally 
hydrolyzed by OXA β-lactamases commonly reported in 
Acinetobacter spp. worldwide.35 OXA-23-producing isolates 
have also been reported in Brazilian hospitals.36 Although 
the production of OXA-23 by itself would not lead to 
high level resistance to carbapenems, OXA-23-producing 
isolates may possess other associated mechanisms of resist-
ance since usually they show high resistance to all carbap-
enems.35,36 Thus, the dissemination of SPM-1-producing 
P. aeruginosa or OXA-23-producing Acinetobacter spp. 
clones in Brazilian hospitals might justify the low suscep-
tibility rates displayed by carbapenenems observed in this 
study that figure amongst the lowest ones observed and 
compared only to the rates of the Asian-Pacific region.37 
Despite of the limited role of carbapenems for the 
treatment of non-fermentative infections in Brazilian 
hospitals, doripenem shows potent in vitro activity com-
pared to that of meropenem. This compound could have its 
clinical benefit maximized by utilizing higher dosages in 
prolonged infusion and might exert a lower selective pres-
sure in the hospital microbiota. In addition, doripenem 
use might have economic and clinical benefit to patients and 
healthcare delivery. Kollef et al.38 assessed medical resource 
utilization in patients with ventilator-associated pneu-
monia through a pooled analysis of two prospective, 
randomized, open-label, multicenter, phase III studies, 
which also showed that doripenem was clinically non-in-
ferior to comparator agents. The authors observed that in 
patients with P. aeruginosa at baseline, median durations of 
mechanical ventilation (7 versus 13 days; p = 0.03) and ICU 
stay (13 versus 21 days; p = 0.02) were shorter for dorip-
enem. Recently, Kongnakorn et al.39 using an economic 
model predicted that doripenem use for treatment of 
ventilator-associated pneumonia would save an average 
of approximately $7,000 per patient compared to imipen-
em, with 95% driven by reduction in hospital length of stay. 
The model predicted 63% less seizures, 52% less emerging 
P. aeruginosa resistance, and 15% shorter stays leading to 
46% less transmission associated with doripenem.
As shown in this study, carbapenems may no longer rep-
resent an effective drug for empirical treatment of infections 
caused by non-fermentative and polymyxins represent the 
last resort drugs for treatment of carbapenem-resistant 
P. aeruginosa or Acinetobacter spp. infections. However, the 
emergence of KPC-producing isolates resistant to polymyx-
ins and all clinical available drugs poses a clinical challenge.40 
Since the high rates of resistance are mainly due to spread of 
endemic clones, infection control measures must be strictly 
applied to restore the activity of carbapenems among non-
fermentative isolates. At this moment, it is imperative the 
establishment of task-force groups to oppose this situation 
at a national level.
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